sellNotable cluster of 3
Bhatnagar Anish sold $47M of SLNO
CHIEF EXECUTIVE OFFICER at SOLENO THERAPEUTICS INC. 699,095 shares at an average of $67.62, traded Mar 27, 2025, filed Mar 31, 2025.
Warning score
70Value
$47M
699,095 shares
Holdings after
577,076
-93% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$47.3M at market
- +20Share of holdings soldSold 93% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-009290, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 27, 2025 | SOpen-market sale Common Stock | -14,183 | $65.97 | $936k | 738,179 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock | -23,095 | $66.79 | $1.5M | 715,084 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock | -41,989 | $67.70 | $2.8M | 673,095 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock | -55,234 | $68.79 | $3.8M | 617,861 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock | -31,980 | $69.84 | $2.2M | 585,881 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock | -3,291 | $70.73 | $233k | 582,590 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock | -4,782 | $71.74 | $343k | 577,808 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock | -732 | $72.64 | $53k | 577,076 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Common Stock | +26,606 | $24.00 | $639k | 603,682 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Common Stock | +16,666 | $25.05 | $417k | 620,348 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Common Stock | +105,000 | $33.60 | $3.5M | 725,348 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Common Stock | +32,193 | $5.10 | $164k | 757,541 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Common Stock | +62,291 | $2.41 | $150k | 819,832 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Common Stock | +281,053 | $5.25 | $1.5M | 1,100,885 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock | -106,471 | $65.81 | $7.0M | 994,414 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock | -209,689 | $66.33 | $14M | 784,725 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock | -8,423 | $67.37 | $567k | 776,302 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock | -199,226 | $69.30 | $14M | 577,076 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Employee stock option (right to buy)derivative | -26,606 | $0.00 | $0 | 60 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Employee stock option (right to buy)derivative | -16,666 | $0.00 | $0 | 0 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Employee stock option (right to buy)derivative | -105,000 | $0.00 | $0 | 35,000 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Employee stock option (right to buy)derivative | -32,193 | $0.00 | $0 | 8,473 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Employee stock option (right to buy)derivative | -62,291 | $0.00 | $0 | 52,709 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Employee stock option (right to buy)derivative | -281,053 | $0.00 | $0 | 200,753 | Mar 31, 2025 |
Related signals
Other insiders at SOLENO THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | SOLENO THERAPEUTICS INC | Michael F. Huang Sr. VP of Clinical Development | $200k 6,582 shares | -14% | |
| 41Moderate | SOLENO THERAPEUTICS INC | Meredith Manning Chief Commercial Officer | $229k 7,522 shares | -10% | |
| 14Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $317k 3,830 shares | -22% | |
| 0Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $22k 266 shares | -2% | |
| 28Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $265k 3,782 shares | -12% | |
| 40Moderate | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $11M 156,315 shares | -139% | |
| 50Moderate | SOLENO THERAPEUTICS INC | Michael F. Huang Sr. VP of Clinical Development | $1.0M 14,583 shares | -35% | |
| 58Moderate | SOLENO THERAPEUTICS INC | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | $966k 21,091 shares | -3% | |
| 34Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $139k 3,030 shares | -3% | |
| 52Moderate | SLNOsell SOLENO THERAPEUTICS INC | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | $785k 18,980 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.